Therefore, to develop a lead compound for lung cancer treatment, we used an FDA-approved drug library with excellent properties and safety measures in places and discovered a hit compound, DES, that inhibits ANO1 and which is currently used as a prostate cancer treatment agent. Here, ANO1 is linked to lung carcinoma.